Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (58)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by MARSHALL, I. G.
Right arrow Articles by DURANT, N. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MARSHALL, I. G.
Right arrow Articles by DURANT, N. N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 1983, Vol. 55, No. 8 703-714
© 1983 The Board of Management and Trustees of the British Journal of Anaesthesia


other

NEUROMUSCULAR AND VAGAL BLOCKING ACTIONS OF PANCURONIUM BROMIDE, ITS METABOLITES, AND VECURONIUM BROMIDE (ORG NC 45)AND ITS POTENTIAL METABOLITES IN THE ANAESTHETIZED CAT

I. G. MARSHALL, PH.D., A. J. GIBB, B.SC. and N. N. DURANT, PH.D.*

Department of Physiology and Pharmacology, University of Strathclyde George Street, Glasgow, G1 1XW.

Correspondence to I.G. M.

The neuromuscular and cardiac vagus blocking actions of pancuronium, vecuronium (Org NC 45) and their respective potential hydroxy metabolites have been studied in the chloralose-anaesthetized cat. Pancuronium was three times more potent as a neuromuscular blocker than its 3-hydroxy derivative, 20 times more potent than the 17-hydroxy derivative and 45 times more potent than the 3,17-dihydroxy derivative. The vagal: neuromuscular block ratios measured at 50% inhibition for these compounds were pancuronium 3.0, 3-hydroxy derivative 6.4, 17-hydroxy derivative 1.1 and 3, 17-dihydroxy derivative 0.36 (a value greater than unity indicated greater potency at the neuromuscular junction). Vecuronium was 1.4 times more potent than its 3-hydroxy derivative, 24 times more potent than the 17-hydroxy derivative and 72 times more potent than the 3,17-dihydroxy derivative as a neuromuscular blocker. The vagal: neuromuscular block ratios were vecuronium 79.8, 3-hydroxy derivative 40.4, 17-hydroxy derivative 0.85 and 3,17-dihydroxy derivative 0.15. The 3-hydroxy derivative of vecuronium, the most Likely first metabolite of vecuronium, thus possessed only slightly less neuromuscular blocking potency than vecuronium, coupled with a high safety margin between neuromuscular and vagal blocking doses. In addition, the time-course of its action was not different from that of vecuronium. Thus, it is concluded that this potential metabolite is unlikely to give rise to tachycardia in man. It is unlikely that the 17-hydroxy and 3,17-dihydroxy derivatives of vecuronium would be produced in sufficiently great quantities by metabolism from vecuronium to result in either tachycardia or residual neuromuscular blockade.

*Present address: Department of Anesthesiology, Center for the Health Science, University of California at Los Angeles ca90024, U.S.A.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Deem, C. M. Lee, and J. R. Curtis
Acquired Neuromuscular Disorders in the Intensive Care Unit
Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 735 - 739.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.